Xiaodi joined Delos in 2022 and has ten years of experience in life sciences research and investment. Prior to Delos, she was a VP at SCVC, focusing on investing in early-stage biotech companies. She has led investments in several leading biotech companies and conducted detailed research and exported reports on 20 biopharmaceuticals industry. She majored in structure biology, studying the structure and function of viral and antibody complexes. Her research was published as the first author in Nature Microbiology.

Xiaodi holds a Ph.D. degree in Biochemistry and Molecular Biology from Institute of Biophysics, Chinese Academy of Sciences and a B.S. degree in Biology from the Northwest A&F University.